Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms

Yifei Xie; Ke Yao; Zigang Dong; Kangdong Liu

doi:10.1016/j.canlet.2021.03.029

Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms

Yifei Xie, Ke Yao, Zigang Dong, Kangdong Liu

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Proliferating cancer cells exhibit metabolic alterations and specific nutritional needs for adapting to their rapid growth. These changes include using aerobic glycolysis, lipid metabolic disorder, and irregular protein degradation. It may be useful to target metabolic abnormalities for cancer chemoprevention. Epidemiological and mechanism-related studies have indicated that many FDA-approved anti-metabolic drugs decrease tumor risk, inhibit tumor growth, or enhance the effect of chemotherapeutic drugs. Drugs targeting nutrient metabolism have fewer side effects with long-term use compared to chemotherapeutic drugs. The characteristics of these drugs make them promising candidates for cancer chemoprevention. Here, we summarize recent discoveries of the chemo-preventive effects of drugs targeting nutrient metabolic pathways and discuss future applications and challenges. Understanding the effects and mechanisms of anti-metabolic drugs in cancer has important implications for exploring strategies for cancer chemoprevention.

Original language	English (US)
Pages (from-to)	1-12
Number of pages	12
Journal	Cancer Letters
Volume	510
DOIs	https://doi.org/10.1016/j.canlet.2021.03.029
State	Published - Jul 10 2021
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported by the National Natural Science Foundation of China [grant number 81872335 ], Natural Science Foundations of Henan [grant number 161100510300 ], and National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China [grant number 2018ZX09711002 ].

Publisher Copyright:
© 2021

Keywords

Cancer chemoprevention
FDA-Approved drugs
Nutrient metabolism

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.canlet.2021.03.029

Find It

Find It at U of M Libraries

Cite this

@article{cc3786e91fec4076a3f3c5eadff29072,

title = "Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms",

abstract = "Proliferating cancer cells exhibit metabolic alterations and specific nutritional needs for adapting to their rapid growth. These changes include using aerobic glycolysis, lipid metabolic disorder, and irregular protein degradation. It may be useful to target metabolic abnormalities for cancer chemoprevention. Epidemiological and mechanism-related studies have indicated that many FDA-approved anti-metabolic drugs decrease tumor risk, inhibit tumor growth, or enhance the effect of chemotherapeutic drugs. Drugs targeting nutrient metabolism have fewer side effects with long-term use compared to chemotherapeutic drugs. The characteristics of these drugs make them promising candidates for cancer chemoprevention. Here, we summarize recent discoveries of the chemo-preventive effects of drugs targeting nutrient metabolic pathways and discuss future applications and challenges. Understanding the effects and mechanisms of anti-metabolic drugs in cancer has important implications for exploring strategies for cancer chemoprevention.",

keywords = "Cancer chemoprevention, FDA-Approved drugs, Nutrient metabolism",

author = "Yifei Xie and Ke Yao and Zigang Dong and Kangdong Liu",

note = "Funding Information: This work was supported by the National Natural Science Foundation of China [grant number 81872335 ], Natural Science Foundations of Henan [grant number 161100510300 ], and National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China [grant number 2018ZX09711002 ]. Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jul,

day = "10",

doi = "10.1016/j.canlet.2021.03.029",

language = "English (US)",

volume = "510",

pages = "1--12",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention

T2 - Drugs and mechanisms

AU - Xie, Yifei

AU - Yao, Ke

AU - Dong, Zigang

AU - Liu, Kangdong

N1 - Funding Information: This work was supported by the National Natural Science Foundation of China [grant number 81872335 ], Natural Science Foundations of Henan [grant number 161100510300 ], and National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China [grant number 2018ZX09711002 ]. Publisher Copyright: © 2021

PY - 2021/7/10

Y1 - 2021/7/10

N2 - Proliferating cancer cells exhibit metabolic alterations and specific nutritional needs for adapting to their rapid growth. These changes include using aerobic glycolysis, lipid metabolic disorder, and irregular protein degradation. It may be useful to target metabolic abnormalities for cancer chemoprevention. Epidemiological and mechanism-related studies have indicated that many FDA-approved anti-metabolic drugs decrease tumor risk, inhibit tumor growth, or enhance the effect of chemotherapeutic drugs. Drugs targeting nutrient metabolism have fewer side effects with long-term use compared to chemotherapeutic drugs. The characteristics of these drugs make them promising candidates for cancer chemoprevention. Here, we summarize recent discoveries of the chemo-preventive effects of drugs targeting nutrient metabolic pathways and discuss future applications and challenges. Understanding the effects and mechanisms of anti-metabolic drugs in cancer has important implications for exploring strategies for cancer chemoprevention.

AB - Proliferating cancer cells exhibit metabolic alterations and specific nutritional needs for adapting to their rapid growth. These changes include using aerobic glycolysis, lipid metabolic disorder, and irregular protein degradation. It may be useful to target metabolic abnormalities for cancer chemoprevention. Epidemiological and mechanism-related studies have indicated that many FDA-approved anti-metabolic drugs decrease tumor risk, inhibit tumor growth, or enhance the effect of chemotherapeutic drugs. Drugs targeting nutrient metabolism have fewer side effects with long-term use compared to chemotherapeutic drugs. The characteristics of these drugs make them promising candidates for cancer chemoprevention. Here, we summarize recent discoveries of the chemo-preventive effects of drugs targeting nutrient metabolic pathways and discuss future applications and challenges. Understanding the effects and mechanisms of anti-metabolic drugs in cancer has important implications for exploring strategies for cancer chemoprevention.

KW - Cancer chemoprevention

KW - FDA-Approved drugs

KW - Nutrient metabolism

UR - http://www.scopus.com/inward/record.url?scp=85104304871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104304871&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2021.03.029

DO - 10.1016/j.canlet.2021.03.029

M3 - Article

C2 - 33857528

AN - SCOPUS:85104304871

SN - 0304-3835

VL - 510

SP - 1

EP - 12

JO - Cancer Letters

JF - Cancer Letters

ER -

Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this